HeartFlow Analysis vs Tempus ECG-Low EF
AI Verdict
Choose HeartFlow Analysis if…
Choose HeartFlow Analysis if you require a comprehensive, non-invasive assessment of coronary artery disease, including both anatomical stenosis and its functional impact. This tool is ideal for patients with suspected or known CAD who need detailed insights into blood flow and plaque characteristics derived from standard CT scans, helping to guide treatment decisions and potentially avoid invasive procedures.
View HeartFlow Analysis →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if you need an efficient, AI-powered screening tool to identify patients aged 40 or older at risk of heart failure by detecting signs of low left ventricular ejection fraction from a standard 12-lead ECG. This solution is best suited for rapid risk stratification in clinical settings to prompt further diagnostic evaluation, such as an echocardiogram, for those identified as having potential low LVEF.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | HeartFlow Analysis | Tempus ECG-Low EF |
|---|---|---|
| Pricing | Contact vendor for pricing | Unknown |
| Deployment | Cloud-based (AWS) | Integrates with current ECG platforms and electronic health records (EHRs). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-Low EFTempus ECG-Low EF provides a straightforward binary output (Low LVEF Detected / Not Detected) from standard ECG recordings, making it highly usable for quick interpretation and integration into fast-paced clinical workflows. HeartFlow Analysis, while valuable, generates detailed 3D models and FFRct values, which may require more specialized review and interpretation time.
Clinical Value
HeartFlow AnalysisHeartFlow Analysis offers a comprehensive, non-invasive diagnostic assessment for coronary artery disease (CAD) by providing FFRct analysis, plaque quantification, and 3D models, directly guiding treatment decisions. Tempus ECG-Low EF serves as a valuable screening tool for low LVEF, aiding in identifying patients at risk of heart failure, but it prompts further evaluation rather than providing a definitive diagnosis for a specific disease.
Pricing & Value
HeartFlow AnalysisHeartFlow Analysis has established Category I CPT codes for FFRct Analysis and AI-Enabled Quantitative Plaque Analysis, with CMS payment rates already in place. This clear reimbursement pathway significantly de-risks adoption for healthcare providers. Tempus ECG-Low EF's pricing and reimbursement details are not specified in the provided information, making its financial value proposition less transparent.
Enterprise Readiness
TieBoth tools demonstrate strong foundational enterprise readiness with FDA clearance, HIPAA compliance, and Business Associate Agreements (BAAs). HeartFlow explicitly mentions cloud-based deployment on AWS, suggesting scalability, while Tempus states integration into healthcare facility workflows. Without more specific details on their respective integration capabilities and enterprise features, it is difficult to definitively distinguish between them.
Innovation
HeartFlow AnalysisHeartFlow Analysis represents a significant innovation by integrating AI with advanced computational fluid dynamics (CFD) to derive functional fractional flow reserve (FFRct) from standard CT scans, offering a non-invasive alternative to invasive FFR. While Tempus ECG-Low EF's application of AI to ECGs for LVEF detection is also innovative, HeartFlow's approach involved a more complex scientific and engineering breakthrough to transform anatomical data into functional insights.
Support & Docs
TieThe provided structured facts do not contain any specific information regarding the availability, quality, or scope of support and documentation for either HeartFlow Analysis or Tempus ECG-Low EF. Therefore, it is not possible to make a comparative judgment on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | HeartFlow Analysis | Tempus ECG-Low EF |
|---|---|---|
| Tool Name | HeartFlow Analysis | Tempus ECG-Low EF |
| Company | HeartFlow | Tempus AI |
| Primary Function | Non-invasive diagnosis and management of coronary artery disease (CAD) via 3D models from CT scans | Detects signs associated with low left ventricular ejection fraction (LVEF u226440%) from 12-lead ECG recordings |
| Data Input | Standard CT scans | 12-lead ECG recordings |
| Key Output | AI-powered 3D modeling of coronary arteries, FFRct analysis, Plaque Analysis, Roadmapu2122 Analysis | Binary output (Low LVEF Detected / Not Detected) |
| Target Condition | Coronary Artery Disease (CAD) | Low Left Ventricular Ejection Fraction (LVEF u226440%) |
Videos
Demos, reviews, and walkthroughs featuring HeartFlow Analysis and Tempus ECG-Low EF.
Frequently Asked Questions
More Comparisons
More matchups featuring HeartFlow Analysis or Tempus ECG-Low EF
Backers
Who funded each tool's parent company.